AIM Immunotech Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 26, 2020, reporting events that occurred on March 24, 2020. The filing pertains to AIM Immunotech Inc., a Delaware corporation trading on the NYSE American under the symbol AIM.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
On March 24, 2020, the Board of Directors approved the following compensatory changes for named executive officers:
- Cash Bonuses:
- Thomas K. Equels (CEO and President): $300,000
- Peter Rodino (COO, General Counsel, & Secretary): $112,500
- Ellen Lintal (CFO): $75,000
- Salary Increases:
- Peter Rodino: Increased from $375,000 to $400,000 annually.
- Ellen Lintal: Increased from $200,000 to $250,000 annually.
The Board cited recent company accomplishments as the basis for these awards.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the immediate compensation event.
Key Facts for Investor Verification
- Verify the total cash outflow of $487,500 in bonuses and the impact on the company's cash position.
- Confirm the effective date of the new annual salary rates for the COO and CFO.
- Review the specific "recent accomplishments" referenced by the Board to justify the compensation increases.